It's worth reading Peter Molloy's profile ... https://www.raceoncology.com/staff/peter-molloy/
IMO ... that's what you're investing in ... he's made other companies money now he wants to make his own one successful. I doubt he'll finish with bisantrene ... I expect he's got another drug or two on his radar.
It's his expertise and experience that is worth more than anything.
The question I ask myself ... what's worth more ... the drug (voucher or not) or the company ... IMO the company including Peter is what people are invested in.
Bisantrene just confirms his model works. (Watch when instos start to try to accumulate!)
(And above all Peter Molloy seems 100% honorable to the shareholders ... a rarity these days.)
AstraZeneca pays Sobi $95M for priority review voucher, page-9
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
-0.040(2.42%) |
Mkt cap ! $274.1M | |||
| Open | High | Low | Value | Volume |
| $1.65 | $1.70 | $1.60 | $229.6K | 139.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 129 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.65 | 2839 | 1 |
View Market Depth
| Last trade - 16.10pm 04/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |